Side-by-side comparison of AI visibility scores, market position, and capabilities
Absci is an AI drug creation company that combines generative AI with a synthetic biology platform to design novel therapeutic proteins from the ground up.
Absci is a publicly traded AI drug creation company founded in 2011 that went public in 2021 and has repositioned around generative AI for drug design. The company operates an integrated platform that uses generative AI to design novel antibodies and proteins, then validates them using high-throughput expression and biological assay systems in its own wet lab infrastructure. Absci's approach treats drug discovery as a generative design problem, using AI to propose protein sequences with desired therapeutic properties and then rapidly testing millions of candidates to identify viable drug leads. The company has established drug creation partnerships with major pharmaceutical companies including AstraZeneca, Merck, and EQT Life Sciences. Absci's technical differentiation lies in its ability to close the loop between AI-generated protein designs and experimental validation at unprecedented scale. The company represents a new category of AI-native biopharmaceutical company that combines computational and wet-lab capabilities to create drugs not discoverable through traditional means.
ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.